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Objectives: to compare graft patency and limb salvage rate following femoro-infrapopliteal bypass using ePTFE grafts
with and without the addition of adjuvant arterio-venous fistula.
Design: a prospectively randomised controlled trial.
Materials: patients referred to two teaching hospital vascular surgery units in the U.K. for the treatment of critical limb
ischaemia.
Methods: eighty-seven patients (M:F; 2.3:1) undergoing 89 femoro-intrapopliteal bypass operations with ePTFE grafts
for critical limb ischaemia were randomly allocated to have AVF included in the operative procedure (n=48) or to a
control group without AVF (n=41). An interposition vein-cuff was incorporated at the distal anastomosis in all patients.
Results: the cumulative rates of primary patency and limb salvage at 1-year after operation for patients with AVF were
55.2% and 54.1% compared to 53.4% and 43.2%, respectively, for the control group. The differences between the AVF
and control groups did not reach statistical significance, in terms of either graft patency or limb salvage, at any stage
after operation (Log-Rank test).
Conclusions: AVF confers no additional significant clinical advantage over interposition vein cuff in patients having
femoro-infrapopliteal bypass with ePTFE grants for critical limb ischaemia.
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Introduction threshold velocity (TTV), below which thrombotic oc-
clusion is likely to occur. The purpose of an adjuvant
High outflow resistance and low velocity of blood AVF is to accelerate blood flow in the graft above
flow leading to thrombotic occlusion of the graft is a the TTV level by supplementing the limited run-off
potential cause of early failure of femorodistal bypass provided by a severely diseased peripheral vascular
surgery, especially when the indication is critical isch- bed. Although AVF has been employed, empirically,
aemia. The alien flow surface presented by prosthetic as an adjunct to femorodistal bypass surgery since
grafts renders them more prone to this complication the early 1980s, and improved results have been
than grafts constructed from autologous veins and this claimed,2–10 its value has not previously been evaluated
may be a factor contributing to their comparatively in a controlled trial.
poor performance. Sauvage1 demonstrated ex- One potential disadvantage of AVF is that the ac-
perimentally that there is a characteristic velocity of celeration of blood flow, by promoting random tur-
blood flow for all graft materials, the thrombotic bulence, may aggravate problems at the distal
anastomosis due to myointimal hyperplasia (MIH).
Following the publication of trial results showing im-
proved patency of ePTFE grafts with interposition vein* Presented at the annual scientific meeting of the Vascular Surgical
Society of Great Britain and Ireland on 26–28th of November 1997. cuffs11, and our own studies which indicate that a vein
† Please address all correspondence to: P. L Harris, Royal Liverpool cuff modifies, beneficially, anastomotic MIH, it hasUniversity Hospital, Department of Vascular Surgery, Prescot Street,
Liverpool, L7 8XP, U.K. been our practice to apply it at the distal anastomosis
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Table 1. Clinical characteristic of patients in AVF and control
groups
AVF Control
Age (mean) 71.5 69.1
Sex M:F 1.4:1 4.8:1
Indication Rest pain Rest pain




Anterior tibial 35% 29%
Peroneal 35% 34%
Posterior tibial 30% 37%
of all prosthetic femoro-infrapopliteal bypasses. There-
fore, the aim of the trial reported here was to determine
whether AVF provided any additional clinical
Fig 1. Common ostium fistula.16
advantage over interposition vein-cuff in patients hav-




The vascular surgical services of two U.K. teaching
hospitals, Royal Liverpool University Hospital, Liver- Fig. 2. Pre-anastomotic fistula.16
pool and Chelsea and Westminster Hospital, London,
participated in this trial. form of Cefotaxime 1.5 gm intravenously at induction.
A total of 89 femoro-infrapopliteal bypasses using Externally supported 6 mm ePTFE grafts (Impra Corp)
ePTFE grafts, carried out in 87 patients with critical were employed in all cases. The distal anastomosis
limb ischaemia, were included between June 1991 and was constructed in end-to-side manner with an in-
June 1997. The mean age of the patients was 70.3 years terposition vein-cuff.13,14
(range 31–89 years) and the male to female ratio was A common ostium fistula (Fig. 1) was constructed
3.2:1. Fourteen were diabetic and 57 admitted to smok- in patients in whom the concomitant veins related to
ing within the last year. All had critical limb ischaemia the recipient artery were judged to be small, and a
as defined by the European Consensus Document.12 pre-anastomotic fistula (Fig. 2) was used in those with
Forty-eight were randomly allocated to receive an larger concomitant veins. In all cases the use of clamps
adjuvant AVF and 41 to a control group. Clinical was avoided, prevention of back bleeding being
characteristics of the patients in each group are shown achieved with fine intraluminal silicone catheters.
in Table 1. Local ethical committee approval was ob- Antiplatelet therapy in the form of aspirin 300 mg
tained prior to the commencement of the trial. Patients, daily was commenced at least 48 h preoperatively. All
who consented to take part, were recruited con- patients received heparin 5000 iu during operation
secutively. Exclusion criteria were: (i) the presence of and anticoagulation was continued for 5 days after
autologous vein suitable for vein graft; (ii) venous operation with a continuous infusion of heparin, the
hypertension due to deep venous obstruction in the dose of which was adjusted to maintain APPT levels
affected limb; (iii) severely compromised cardiac func- within a therapeutic range of 2–3 times normal value.
tion. All patients were discharged on oral warfarin in ad-
dition to the aspirin which had been commenced
preoperatively, this anticoagulation regime being con-
tinued indefinitely.Surgical technique
Follow-up was by clinical examination and duplex
ultrasound scanning in the vascular laboratory at 6Patients were operated upon under general an-
aesthesia and received antibiotic prophylaxis in the weeks 3, 6, 9 and 12 months after operation and then
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Fig. 3. Cumulative survival rate of all patients. adjusted number Fig. 4. Primary cumulative patency rates of the AVF group in
aof patients at risk. continuous line (—) and the control group in dashed line (· · · · · ·).
*Adjusted number of patients at risk of the AVF group
**Adjusted number of patients at risk of the control group
at variable intervals thereafter. All patients in whom
graft occlusion was suspected were investigated fur-
ther by angiography.
The results, in terms of graft patency and limb
salvage, were analysed by calculation of Kaplan–Meier
curves,15 and Log-Rank test was applied to test for
statistical significance.
Results
Five patients died within 30 days of operation, giving
a perioperative mortality rate of 5.6%. The cumulative
survival rate of all patients at 6, 12, and 24 months
Fig. 5. Secondary cumulative patency rates of the AVF group inwas 91%, 85.3% and 81.6%, respectively (Fig. 3).
continuous line (—) and the control group in dashed lines (· · · · · ·).The construction of an adjuvant AVF increased the *Adjusted number of patients at risk of the AVF group
operating time by an average of approximately 30 min. **Adjusted number of patients at risk of the control group
In the AVF group five grafts occluded within the
first month after operation and this was followed by with AVF and controls are shown in Figs 4, 5 and 6.
early loss of the limb in four. Another 15 grafts became There was no statistically significant difference be-
occluded within the first year, only one of which was tween the two groups with respect to primary and
re-explored with restoration of patency. This graft secondary patency rate (p>0.2 Log-Rank test) or limb
became occluded again within 14 h. salvage rate (p<0.3 Log-Rank test) at any stage after
In the control group 10 grafts occluded within the operation. A trend towards better early patency of
first month and this was followed by early amputation grafts with adjuvant AVF diminished progressively
in seven. One patient underwent thrombolysis and re- after the first 6 months.
exploration with the elective addition of an AVF that
restored graft patency for another 6 months. Another
14 grafts in the control group occluded within the first
year, two of which were re-explored and one treated Discussion
by thrombolysis followed by angioplasty of the inflow
vessel (Tables 5, 6). A worthwhile period of patency A previously reported study from Liverpool16 in-
dicated that, although interposition vein-cuff (VC) didwas restored in only one of these patients.
The primary and secondary cumulative patency improve the patency rate of long, distal ePTFE grafts
in keeping with the findings of the JVRG (Joint Vascularrates and the cumulative limb salvage rate for patients
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cited as potential complications of adjuvant AVF. In
this trial deep veins only were used for the construction
of the AVF and patients with a known history of deep
vein thrombosis in the relevant limb were excluded.
Only two patients developed evidence of clinically
significant venous hypertension. It is known that a
steal of blood from the foot is likely to occur only if
inflow to the graft is impeded18 and care was taken to
ensure that this situation was avoided. Although one
patient in the AVF group required amputation despite
a patent graft, this was attributable to a large volume
of irreversible ischaemia within the foot. No clinical
consequences due to steal phenomena were recognised
in any of the patients.
Extremely low patency rates, of 30% or less, reportedFig. 6. Cumulative limb salvage of the AVF group in continuous
line (—) and the control group in dashed line (· · · · · ·). from the use of ePTFE grafts for femoro-infrapopliteal
*Adjusted number of patients at risk of the AVF group bypass have fuelled the controversy concerning the
**Adjusted number of patients at risk of the control group
relative merits of reconstruction and primary am-
putation in the absence of autologous vein. However,
Research Group) trial,11 the effect of AVF was rather cumulative patency rates in excess of 50% after the
more dubious. A prospectively randomised controlled first year for ePTFE grafts with interposition vein cuff,
trial was required to establish whether or not AVF has as reported by the Joint Vascular Research Group of
any clinical value. Great Britain and Ireland11 and again here, suggest
The reported results of autologous vein grafts for that reconstruction is certainly the best option for the
femoro-infrapopliteal bypass are considerably majority of patients. However, the results of this trial
superior to those of prosthetic grafts including ePTFE.17 indicate that the addition of AVF confers no worth-
Therefore, autologous vein is used in preference to while advantage above that which can be achieved
ePTFE whenever possible, and this accounts for the with interposition vein cuff alone. Therefore, the ap-
fact that two large vascular surgery units were able to plication of adjuvant AVF as routine is not justified.
recruit into this trial only 87 patients in 6 years. The Many surgeons can report anecdotal experience of
relatively small number of patients undermines the having secured worthwhile patency of a graft fol-
power of the trial and it is possible that a significant lowing early secondary intervention that included the
early advantage for AVF, in terms of primary patency, construction of an AVF. One graft in the present series
may have been masked by a type two statistical error. remained patent for 6 months under these cir-
However, the observed early trend in favour of AVF cumstances. In this context the following points are
diminished progressively after the first 6 months. The worth making; first, harmful effects attributable to
rates of limb salvage in AVF and control groups were AVF are rare, and second, the results of this trial cannot
very closely matched at all stages after operation. be taken to exclude the possibility that individual
Therefore it is probably safe to conclude from the patients may occasionally benefit from the application
results of this trial that AVF confers no durable clinical of AVF under exceptional circumstances.
benefit. In summary, the results of this prospectively ran-
It would be interesting to know what proportion of domised trial do not show evidence of worthwhile
adjuvant A–V fistulae remained patent and whether benefit associated with AVF, in terms of either graft
closure of the fistula increased the risk of graft failure. patency or limb salvage rates, and it is concluded,
Graft thrombosis was always accompanied by closure therefore, that there is no indication for its routine
of the fistula, and it was not possible to determine application with prosthetic femoro-infrapopliteal by-
which occurred first in these circumstances. A small pass grafts.
number of grafts have remained patent despite closure
of the AVF, but the great majority of patent grafts in
the AVF group also had a patent AVF. The absence of References
precise information in this respect does not undermine
1 Sauvage LR, Walter MW, Berger K et al. Current arterialthe principle conclusion that can be drawn from the
prostheses. Experimental evaluation by implantation in the ca-trial. rotid and circumflex coronary artery of the dog. Arch Surg 1979;
114: 687–691.Venous hypertension and steal phenomena are often
Eur J Vasc Endovasc Surg Vol 17, March 1999
Adjunctive Distal Arteriovenous Fistula 201
2 Dardik H, Berry S, Dardik A et al. Infrapopliteal prosthetic 11 Stonebridge PA, Prescott RJ, Ruckley CV. Randomised trial
comparing infra-inguinal polytetrafluoroethylene bypass graft-graft patency by use of the distal adjunctive arteriovenous fistula.
J Vasc Surg 1991; 13: 685–691. ing with and without vein interposition cuff at the distal ana-
stomosis. The Joint Vascular Research Group. J Vasc Surg 1997;3 Davis P, Henegonwen B, Stelzer G et al. Pedal and distal lower
leg bypasses with a distal arteriovenous fistula. Eur J Vasc Surg 26: 543–550.
12 European Working Group on Critical Leg Ischaemia. Second1987; 1: 251–258.
4 Jacobs M, Reul G, Gregoric I et al. Creation of a distal arterio- European Consensus Document on chronic critical leg ischaemia.
Circulation 1991; 84 (Suppl. 4): 1–26.venous fistula improves microcirculatory hemodynamics of pro-
sthetic graft bypass in secondary limb salvage procedures. J Vasc 13 Miller JH, Formann RK, Ferguson L, Faris I. Interposition
vein-cuff for anastomosis of prosthesis to small artery. Aust NZSurg 1993; 18: 1–9.
5 Ibrahim I, Susman B, Dardik I et al. Adjunctive arteriovenous J Surg 1984; 54: 283–285.
14 Harris PL. Adjuvant arteriovenous fistula at the distal ana-fistula with tibial and peroneal reconstruction for limb salvage.
stomosis of a femorotibial bypass graft. In: Greenhalgh RM, ed.Am J Surg 1980; 140: 246–251.
Vascular Surgical Technique: An Atlas. London, England: WB6 Charlesworth PM, Brewster DA, Darling RC et al. The fate
Saunders, 1989; 306–309.of polytetrafluorethylene grafts in lower limb bypass surgery: 6-
15 Underwood CJ, Faragher EB, Charlesworth D. The uses andyear follow-up. Br J Surg 1985; 72: 896–899.
abuses of life table analysis in vascular surgery. Br J Surg 1984;7 Parsons R, Suggs W, Veith F et al. Polytetrafluoroethylene
71: 495–498.bypasses to infrapopliteal arteries without cuff or patches: a
16 Harris PL, Bakran A, Enabi L et al. ePTFE Grafts for Femoro-better option than amputation in patients without autologous
crural bypass-improved results with combined adjuvant venousvein. J Vasc Surg 1996; 23: 347–356.
cuff and arteriovenous fistula? Eur J Vasc Surg 1993; 7: 528–533.8 Kortmann H, Orend KH, Abendroth D, Becker HM. Crural
17 Veith FJ, Gupta SK, Ascer E et al. Six-year prospective multi-arterial reconstruction with adjuvant arteriovenous fistula for
centre randomised comparison of autologous saphenous veinlimb salvage. Thorac Cardiovasc Surgeon 1985; 33: 382–384.
and expanded polytetrafluoroethylene grafts in infrainguinal9 Ascer E, Gennaro M, Pollina RM et al. Complementary distal
arterial reconstructions. J Vasc Surg 1986; 3: 104–114.arteriovenous fistula and deep vein interposition: a 5-year ex-
18 Campbell H, How TV, Harris PL. Experimental evaluation ofperience with a new technique to improve infrapopliteal pros-
arterial steal in in vitro models of femoro-tibial bypass withthetic bypass patency. J Vasc Surg 1996; 24: 134–143.
aduvant A–V shunt. Clin Phys Physiol Measurement 1984; 5:10 Dardik H, Silvestri F, Alasio T et al. Improved method to
253–262.create the common ostium variant of the distal arteriovenous
fistula for enhancing crural prosthetic graft patency. J Vasc Surg
1996; 24: 240–248. Accepted 10 June 1998
Eur J Vasc Endovasc Surg Vol 17, March 1999
